• 1
    Brusamolino E, Baio A, Orlandi E et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006; 12: 648793.
  • 2
    Hodgson DC, Pintilie M, Gitterman L et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007; 25: 115.
  • 3
    Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 348494.
  • 4
    Green DM, Hyland A, Barcos MP et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 2000; 18: 14929.
  • 5
    Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002; 94: 18292.
  • 6
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21: 34319.
  • 7
    Oeffinger KC, Mertens AC, Sklar CA et al. Childhood Cancer Survivor S. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 157282.
  • 8
    Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 28317.
  • 9
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993; 270: 194955.
  • 10
    Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 313948.
  • 11
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 187886.
  • 12
    Portlock CS, Boland P, Hays AP, Antonescu CR, Rosenblum MK. Nemaline myopathy: a possible late complication of Hodgkin’s disease therapy. Hum Pathol 2003; 34: 8168.
  • 13
    Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg 2004; 20: 14952.
  • 14
    Matasar MJ, McCallen LN, Reidel ER, Ford JS, Oeffinger KS, Straus D. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol (2009 ASCO Ann Meeting Proc) 2009;27 (Suppl) Part I 445s (abstract 8547).
  • 15
    De Bruin ML, Sparidans J, van’t Veer MB et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27: 423946.
  • 16
    Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007; 357: 191627.
  • 17
    Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 2001; 19: 423844.
  • 18
    Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:893.
  • 19
    Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 312835.
  • 20
    Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495502.
  • 21
    Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010; 363: 64052.
  • 22
    Eich HT, Diehl V, Görgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199206.
  • 23
    O’Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin’s lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28: 12329.
  • 24
    Longo DL, Russo A, Duffey PL et al. Treatment of advanced-stage massive mediastinal Hodgkin’s disease: the case for combined modality treatment. J Clin Oncol 1991; 9: 22735.
  • 25
    Behar RA, Horning SJ, Hoppe RT. Hodgkin’s disease with bulky mediastinal involvement: effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 1993; 25: 7716.
  • 26
    Savage KJ, Connors JM, Wilson D et al. FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalites on post chemotherapy CT scan. Blood 2007;110(ASH Annual Meeting Abstracts):Abstract 213.
  • 27
    Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 34839.
  • 28
    Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 463442.
  • 29
    Eghbali H, Brice P, Creemers G-Y et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin’s lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. Blood. [abstract]. 2005;106(11):240a, abstract #814.
  • 30
    Noordijk EM, Carde P, Mandard AM et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin’s disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994; 5(Suppl 2): 10712.
  • 31
    Rueda Dominguez A, Marquez A, Guma J et al. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15: 1798804.
  • 32
    Olcese F, Clavio M, Rossi E et al. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. Ann Hematol 2009; 88: 85561.
  • 33
    Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010; 28: 16115.
  • 34
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004; 22: 283541.
  • 35
    Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 761420.
  • 36
    Rueda A, Sevilla I, Guma J et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin’s lymphoma with ABVD. Leuk Lymphoma 2001; 4: 3538.
  • 37
    Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42: 297681.
  • 38
    Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008; 49: 15306.
  • 39
    Evens AM, Cilley J, Ortiz T et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 54552.
  • 40
    Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 8(Suppl 2): S636.
  • 41
    Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 26159.
  • 42
    Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica 2000; 85: 9269.
  • 43
    Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007; 18: 10719.
  • 44
    Straus DJ, Johnson JL, Lacasce AS et al. Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011; 117: 531420.
  • 45
    Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
  • 46
    Cheson BD, Pfistner B, Juweid ME et al. , International Harmonization Project on L. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 57986.
  • 47
    Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004; 22: 15323.
  • 48
    Sieniawski M, Franklin J, Nogova L et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol 2007; 25: 20005.
  • 49
    Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 29304.
  • 50
    Kostakoglu L, Goldsmith SJ, Leonard JP et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 267887.
  • 51
    Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 11608.
  • 52
    Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 529.
  • 53
    Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 374652.
  • 54
    Pavlovsky S, Pavlovsky A, Fernandez I et al. PET-CT adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma. Interim analysis in 173 patients. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 1772.
  • 55
    Radford J, O’Doherty M, Barrington S et al. , T I. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a ‘negative’ FDG-PET scan after 3 cycles ABVD. Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract 369.
  • 56
    Radford J, O’Doherty M, Barrington S et al. Results of the 3rd planned interim analysis of the UK NCRI RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages IA/IIA Hodgkin lymphoma and a ‘negative’ 18-FDG-PET scan after 3 cycles ABVD (Abstract P059). Haematologica (8th International Symposium on Hodgkin Lymphoma) 2010; 95(Suppl. 4): S167.
  • 57
    Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003; 348: 238695.
  • 58
    Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 9059.
  • 59
    Metzger ML, Howard SC, Hudson MM et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2006; 46: 3149.
  • 60
    Bowers DC, McNeil DE, Liu Y et al. Stroke as a late treatment effect of Hodgkin’s Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 27: 650815.